Stem Cell Inducer Composition for Rapid Estradiol-Secreting Differentiation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells are inefficient, complex, and time-consuming, with potential genetic changes and cancer risks, and lack a clear mechanism for differentiation induction.

Innovation Solution

An inducer comprising BMP4, BMP7, RA, resveratrol, icariin, benzamide, chloroplatinic acid hexahydrate, ethanolamine, EPO, and VEGF in specific concentration ratios is used in a human mesenchymal stem cell serum-free culture medium to enhance differentiation efficiency and cell viability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If traditional in vitro induction methods are used to differentiate mesenchymal stem cells into estradiol-secreting cells, then differentiation can be achieved, but the induction efficiency is low, the process is complicated, and the induction time is long

Engineering Contradiction:
Improveinduction efficiencyVSAvoidinduction process complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent changes the chemical parameters of the induction system by introducing a small molecule chemical inducer that activates the Wnt/β-catenin signaling pathway. This chemical induction approach replaces the complex multi-factor in vitro induction system, simplifying the induction process while significantly improving induction efficiency and reducing induction time

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent extracts and isolates the key differentiation-inducing component by using a specific small molecule chemical that targets the Wnt/β-catenin pathway. This extraction approach removes the complexity of using multiple growth factors and stimulating factors, achieving differentiation induction through a single optimized chemical compound

Inventive Principle:
Principle #2Taking out (Extraction)

2Productivity

If traditional in vitro induction methods are used, then differentiation can be achieved, but the induction time is long and the number of resulting cells is small

Engineering Contradiction:
Improvenumber of resulting cellsVSAvoidinduction time
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

By changing the induction mechanism from multi-factor stimulation to targeted chemical induction of the Wnt/β-catenin pathway, the patent accelerates the differentiation process. This parameter change in the induction approach reduces induction time while increasing the yield of functional estradiol-secreting cells

Inventive Principle:
Principle #35Parameter changes

3Productivity

If gene modification or protein transduction is used to induce differentiation, then differentiation efficiency may be improved, but there is a risk of genetic changes and cancer development

Engineering Contradiction:
Improveinduction efficiencyVSAvoidgenetic changes and cancer risk
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces genetic and protein-based induction methods with small molecule chemical induction. This substitution eliminates the need for gene transfection or protein transduction, thereby avoiding the risks of genetic changes and cancer while maintaining high induction efficiency through chemical activation of the Wnt/β-catenin pathway

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent uses small molecule chemicals that can be easily added and removed from the culture system, replacing complex genetic modification procedures. These chemical inducers provide temporary, controllable activation of differentiation pathways without permanent genetic changes, ensuring safety while achieving high induction efficiency

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS12559727B2Inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells
Publication Date: 2026.02.24 QINGDAO RESTORE BIOTECHNOLOGY CO LTD

AI summary

The present disclosure belongs to the field of biological medicines, and relates to an inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells uses human mesenchymal stem cell serum-free culture medium as a substrate and comprises the following components in mass concentration ratios: 20-60 mg/L of bone morphogenetic protein-4, 20-60 mg/L of bone morphogenetic protein-7, 2-8 mg/L of retinoic acid, 2-8 mg/L of resveratrol, 2-8 mg/L of icariin, 2-8 μg/L of benzamide, 2-8 μg/L of chloroplatinic acid hexahydrate, 2-8 μg/L of ethanolamine, 2-10 μg/L of erythropoietin and 2-10 μg/L of vascular endothelial growth factor. The inducer for inducing differentiation of mesenchymal stem cells into estradiol-secreting cells provided by the present disclosure has a high induction efficiency.